BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32272500)

  • 1. Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.
    Corallo S; Fucà G; Morano F; Salati M; Spallanzani A; Gloghini A; Volpi CC; Trupia DV; Lobefaro R; Guarini V; Milione M; Cattaneo L; Antista M; Prisciandaro M; Raimondi A; Sposito C; Mazzaferro V; de Braud F; Pietrantonio F; Di Bartolomeo M
    Oncologist; 2020 Sep; 25(9):780-786. PubMed ID: 32272500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
    Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Shin J; Park YS; Moon MS; Kang YK
    Gastric Cancer; 2024 Jan; 27(1):146-154. PubMed ID: 38006567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
    Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
    BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
    Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma.
    Borozan I; Zapatka M; Frappier L; Ferretti V
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer.
    Soldan SS; Anderson EM; Frase DM; Zhang Y; Caruso LB; Wang Y; Deakyne JS; Gewurz BE; Tempera I; Lieberman PM; Messick TE
    Gastric Cancer; 2021 Sep; 24(5):1076-1088. PubMed ID: 33929613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
    Yang N; Wu Y; Jin M; Jia Z; Wang Y; Cao D; Qin L; Wang X; Zheng M; Cao X; Jiang J
    PeerJ; 2021; 9():e11481. PubMed ID: 34046266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report.
    An G; He XC; Bai J; Wang J
    Medicine (Baltimore); 2023 Mar; 102(13):e33377. PubMed ID: 37000076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
    Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
    J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collision of Epstein-Barr virus-positive and -negative gastric cancer, diagnosed by molecular analysis: a case report.
    Miyabe K; Saito M; Koyama K; Umakoshi M; Ito Y; Yoshida M; Kudo-Asabe Y; Saito K; Nanjo H; Maeda D; Matsusaka K; Goto A; Kono K
    BMC Gastroenterol; 2021 Mar; 21(1):97. PubMed ID: 33653296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma.
    Song HJ; Srivastava A; Lee J; Kim YS; Kim KM; Ki Kang W; Kim M; Kim S; Park CK; Kim S
    Gastroenterology; 2010 Jul; 139(1):84-92.e2. PubMed ID: 20398662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtraction of Epstein-Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases.
    Huang SC; Ng KF; Yeh TS; Cheng CT; Lin JS; Liu YJ; Chuang HC; Chen TC
    Int J Cancer; 2019 Dec; 145(12):3218-3230. PubMed ID: 30771224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
    Hewitt LC; Inam IZ; Saito Y; Yoshikawa T; Quaas A; Hoelscher A; Bollschweiler E; Fazzi GE; Melotte V; Langley RE; Nankivell M; Cunningham D; Allum W; Hutchins GG; Grabsch HI
    Eur J Cancer; 2018 May; 94():104-114. PubMed ID: 29550565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of the Epstein Barr virus on gastric cancer in Peru].
    Beltrán Gárate B; Camara A; Kapsoli Sánchez MDC; Castro Uriol D; Yábar Berrocal A
    Rev Gastroenterol Peru; 2019; 39(4):319-322. PubMed ID: 32097390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.
    Biesma HD; Soeratram TTD; Sikorska K; Caspers IA; van Essen HF; Egthuijsen JMP; Mookhoek A; van Laarhoven HWM; van Berge Henegouwen MI; Nordsmark M; van der Peet DL; Warmerdam FARM; Geenen MM; Loosveld OJL; Portielje JEA; Los M; Heideman DAM; Meershoek-Klein Kranenbarg E; Hartgrink HH; van Sandick J; Verheij M; van de Velde CJH; Cats A; Ylstra B; van Grieken NCT
    Gastric Cancer; 2022 May; 25(3):640-651. PubMed ID: 35129727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-associated gastric carcinoma in Cali, Colombia.
    Carrascal E; Koriyama C; Akiba S; Tamayo O; Itoh T; Eizuru Y; Garcia F; Sera M; Carrasquilla G; Piazuelo MB; Florez L; Bravo JC
    Oncol Rep; 2003; 10(4):1059-62. PubMed ID: 12792770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma.
    Min BH; Tae CH; Ahn SM; Kang SY; Woo SY; Kim S; Kim KM
    Gastric Cancer; 2016 Jul; 19(3):852-9. PubMed ID: 26265391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Implication of EBV Infection in Gastric Carcinomas: A Systematic Review and Meta-Analysis.
    Pyo JS; Kim NY; Kang DW
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.